Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tumor necrosis factor receptor superfamily member 4 (TNFRSF4), also known as OX40 or CD134, is a type I transmembrane glycoprotein and a potent costimulatory receptor primarily expressed on activated T cells. It belongs to the tumor necrosis factor receptor (TNFR) superfamily and interacts with its ligand, OX40L (TNFSF4), which is typically expressed on antigen-presenting cells like dendritic cells and B cells. The OX40-OX40L interaction is crucial for the survival and expansion of effector T cells and the development of memory T cells, while also inhibiting the suppressive function of regulatory T cells (Tregs). In oncology, agonistic antibodies targeting OX40 are designed to enhance anti-tumor immunity by boosting T-cell activity and overcoming the immunosuppressive tumor microenvironment. In contrast, for autoimmune and inflammatory diseases such as atopic dermatitis, antagonistic antibodies or OX40-depleting agents are used to reduce the activity of pathogenic T cells. While OX40-targeted therapies show promise, clinical development faces challenges including the risk of cytokine release syndrome and the need for precise patient selection based on receptor expression levels. Current research is also exploring the synergy of OX40 agonists with other checkpoint inhibitors like PD-1 blockers to improve therapeutic outcomes in solid tumors.
Agonism of costimulatory signaling to enhance T-cell effector function (oncology); Antagonism or depletion of activated T cells to suppress immune response (autoimmune/inflammatory).
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tumor necrosis factor receptor superfamily member 4 (OX40) (OX40).